Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is expected on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as initiating phase 1 clinical trials for BMB-105 and additional R&D for earlier phase programs [3]. Group 3: Company Background - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [8].